# Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways

> **NCT05124288** · — · RECRUITING · sponsor: **Ciceri Fabio** · enrollment: 500 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse

## Interventions

- **OTHER:** Observations on Relapsed AML Allogeneic Transplanted patients

## Key facts

- **NCT ID:** NCT05124288
- **Lead sponsor:** Ciceri Fabio
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-18
- **Primary completion:** 2026-12-20
- **Final completion:** 2027-06-20
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-05-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05124288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05124288, "Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05124288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*